Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Eve vs Omzo

Eve
Graded #189

Higher grade

vs+12.099999999999994
Omzo
Graded #458

Lower grade

The verdict

Eve takes it — 66.3/100 to 54.2/100.

Eve grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eve is a women's-health-focused GLP-1 telehealth platform — distinctive positioning in a largely gender-neutral market — offering both compounded semaglutide and tirzepatide (including an oral sublingual…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEve +10
55
45
Dose & formulationEve +48
88
40
Clinical oversightEve +3
79
76
Labs & monitoringEven
52
52
FulfillmentEve +4
67
63
Contract termsOmzo +14
41
55
Eve · left barOmzo · right bar

The numbers

MetricEveOmzo
WeighScore66.3/10054.2/100
GradeCC
Scorecard rank#189#458
Semaglutide$195/mo (compounded)Not disclosed
Tirzepatide$195/mo (compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
Eve

Graded #189 · C

Strengths

  • Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
  • Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
  • LegitScript Certified with a verifiable ID
  • Publishes the FDA compounded-medication disclaimer
  • Oral sublingual semaglutide offered alongside injectable

Where it loses points

  • Full states-served list not disclosed publicly
  • 503A pharmacy partner not named, and 503A vs 503B status not specified
  • Named medical director / clinical leadership not disclosed
  • Corporate legal entity not disclosed
  • Governing law / arbitration venue not stated
Omzo

Graded #458 · C

Strengths

  • Compounded GLP-1 (semaglutide and tirzepatide) with clinician guidance
  • Free, discreet delivery on all treatments
  • FSA/HSA eligible
  • Multi-pillar: also women's hormone, sexual health, hair, skin, and daily health

Where it loses points

  • Pricing not published on the site — shown only after the intake quiz
  • Compounding pharmacy partner not named (states only 'independent state-licensed')
  • States of operation not published
  • Not LegitScript-certified (no certification displayed)
  • Legal entity not named; governing law given only as 'the state in which Omzo operates'

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard